论文部分内容阅读
目的探讨血清(Human epididymis protein 4,HE4)联合CA125检测在卵巢癌术后复发中诊断价值。方法收集2013年10月-2016年2月在柳州市妇幼保健院和柳州市柳铁中心医院住院治疗的上皮性卵巢癌病例76例,其中术后复发51例,纳入复发组;术后完全缓解11例,纳入缓解组;初诊14例(未进行手术治疗),纳入初治组。另外收集健康人员35例作为健康对照组。比较各组血清HE4、CA125含量差异,对比两者单独和联合检测在卵巢癌复发患者中的诊断敏感性。结果复发组HE4、CA125水平明显高于缓解组和健康对照组(P<0.05),与初诊组比较无统计学差异(P>0.05),缓解组HE4、CA125水平与健康对照组比较无统计学差异(P>0.05)。联合检测HE4、CA125的敏感性明显高于单纯检测(P<0.05)。结论HE4联合CA125检测可进一步提高卵巢癌术后复发的筛查敏感度,具有较高的临床应用价值。
Objective To investigate the diagnostic value of serum (Human epididymis protein 4, HE4) combined with CA125 in the diagnosis of postoperative recurrence of ovarian cancer. Methods Totally 76 cases of epithelial ovarian cancer hospitalized in Liuzhou Maternal and Child Health Hospital and Liuzhou Central Iron and Steel Hospital from October 2013 to February 2016 were recruited. Among them, 51 cases were recurrent postoperatively, and were included in the recurrent group. The complete remission Eleven cases were included in the remission group; 14 cases were newly diagnosed (no surgical treatment) and were included in the untreated group. Another 35 healthy people were collected as a healthy control group. The serum levels of HE4 and CA125 in each group were compared. The diagnostic sensitivity of the two groups in the diagnosis of ovarian cancer recurrence alone and in combination was compared. Results The levels of HE4 and CA125 in recurrence group were significantly higher than those in remission group and healthy control group (P <0.05), and there was no significant difference between the two groups (P> 0.05). The levels of HE4 and CA125 in remission group were not statistically different from those in healthy control group Difference (P> 0.05). The sensitivity of combined detection of HE4 and CA125 was significantly higher than that of simple detection (P <0.05). Conclusion HE4 combined with CA125 detection can further improve screening sensitivity of ovarian cancer recurrence, which has a high clinical value.